Registered title, quoted from ClinicalTrials.gov
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 10 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 10
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Nantong University南通大学附属医院NantongHospital page
- Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
- Study sitePeking University Shenzhen Hospital北京大学深圳医院ShenzhenHospital page
- Study siteShenzhen People's Hospital深圳市人民医院ShenzhenHospital page
- Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
- Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
- Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
- Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06709274, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Non-small cell lung cancer (NSCLC) confirmed by histological and/or cytological examination. Invasive subtypes are required for adenocarcinomas.
Inclusion criterion 1
Stage IA or IB after surgery based on pathological TNM8 staging criteria established by the International Union Against Cancer/American Joint Committee on Cancer (8th Edition).
Inclusion criterion 2
Complete recovery from surgery with no evidence of disease progression within 2 weeks prior to the first treatment decision.
Inclusion criterion 4
Previous use of any traditional Chinese medicine with anti-tumor properties, or use of such medicine within 2 weeks prior to surgery.
Exclusion criterion 6
Blood transfusion within 2 weeks prior to and during the surgery.
Exclusion criterion 20
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
Inclusion criterion 5
Absolute neutrophil count ≥1.5×10\^9/L
Inclusion criterion 8
Platelet count ≥100×10\^9/L
Inclusion criterion 9
Hemoglobin ≥90 g/L
Inclusion criterion 10
ALT ≤2.5× upper limit of normal (ULN)
Inclusion criterion 11
AST ≤2.5×ULN
Inclusion criterion 12
Total Bilirubin (TBL) ≤1.5×ULN Renal function: Creatinine level ≤1.25×ULN, or creatinine clearance ≥60 mL/min (measured or calculated using the Cockcroft-Gault formula).
Inclusion criterion 13
History of other malignancies within the past 5 years, with the exception of the following:
Exclusion criterion 7
Other malignancies fully cured by surgery with a disease-free survival of more than 10 years
Exclusion criterion 8
Participants regardless of sex must agree to use effective contraception during the study period and for 3 months following treatment completion.
Inclusion criterion 16
Pregnant or breastfeeding females.
Exclusion criterion 22
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06709274, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Non-small cell lung cancer (NSCLC) confirmed by histological and/or cytological examination. Invasive subtypes are required for adenocarcinomas.
- Stage IA or IB after surgery based on pathological TNM8 staging criteria established by the International Union Against Cancer/American Joint Committee on Cancer (8th Edition).
- Completely surgical resection (R0) of the primary NSCLC via lobectomy, segmentectomy, or sleeve lobectomy. The gross tumor must be entirely removed, and all surgical margins of the excised tumor must be negative.
- Complete recovery from surgery with no evidence of disease progression within 2 weeks prior to the first treatment decision.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
- Minimum life expectancy of ≥12 weeks.
- Demonstrate adequate organ function, including:
Hematological parameters:
- Absolute neutrophil count ≥1.5×10\^9/L
- Platelet count ≥100×10\^9/L
- Hemoglobin ≥90 g/L
Liver function:
- ALT ≤2.5× upper limit of normal (ULN)
- AST ≤2.5×ULN
- Total Bilirubin (TBL) ≤1.5×ULN Renal function: Creatinine level ≤1.25×ULN, or creatinine clearance ≥60 mL/min (measured or calculated using the Cockcroft-Gault formula).
- Male or female, age between 18 and 75 years.
- Written informed consent must be obtained from the subject or their legal representative.
- Participants regardless of sex must agree to use effective contraception during the study period and for 3 months following treatment completion.
- Willingness and ability to comply with visit schedules, treatment plans, and laboratory assessments.
Exclusion Criteria:
- Histopathologically confirmed small cell carcinoma components.
- Presence of multiple pulmonary nodules.
- Incomplete resections (R1/R2) or resections via bilateral lobectomy, pneumonectomy, or wedge resection.
- A history of any systemic anti-tumor treatment, including but not limited to surgery, neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
- Significant allergies to any targeted drugs, immunotherapies, or chemotherapy agents used in the study.
- Previous use of any traditional Chinese medicine with anti-tumor properties, or use of such medicine within 2 weeks prior to surgery.
- History of other malignancies within the past 5 years, with the exception of the following:
- Other malignancies fully cured by surgery with a disease-free survival of more than 10 years
- Curable basal cell carcinoma of the skin
- Bladder carcinoma in situ
- Cervical carcinoma in situ
- History of interstitial lung disease, drug-induced interstitial lung disease, radiation-induced pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease.
- Active hepatitis B, defined as HBsAg positive with an HBV-DNA copy number exceeding the ULN established by the study center, accompanied by abnormal liver function, or requiring treatment as evaluated by the investigator.
- Presence of any unstable systemic disease, including but not limited to active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past 3 months, serious arrhythmias that requires medication, liver disease, kidney disease, or metabolic disorders.
- Evidence of any other diseases, neurological or metabolic disorders, or physical exam or laboratory findings that may suggest contraindications for the investigational drug, or a high risk for treatment-related complications.
- Any of the following cardiac conditions:
- Resting ECG QT interval (QTc) > 470 msec.
- Significant abnormalities in rhythm, conduction, or morphology on resting ECG, including complete left bundle branch block, third-degree atrioventricular block, or second-degree atrioventricular block
- Factors increasing the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death in a first-degree relative under the age of 40, or use of medications known to prolong QT interval.
- Blood transfusion within 2 weeks prior to and during the surgery.
- History of alcohol or drug abuse.
- Pregnant or breastfeeding females.
- Any other factors that the investigator deems may affect the progress of the study or compromise the trial data
Quoted from ClinicalTrials.gov, NCT06709274, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06709274, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.